Do analysts prefer CVAC or DNLI?

Denali Therapeutics has a consensus price target of $34.25, indicating a potential upside of 32.60%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Denali Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.81

Do analysts prefer CVAC or NAMS?

NewAmsterdam Pharma has a consensus price target of $49.00, suggesting a potential upside of 40.68%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83

Which has better valuation & earnings, CVAC or NAMS?

CureVac has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 NewAmsterdam Pharma $22.50M 180.96 -$203.82M -$1.79 N/A

Do analysts recommend CVAC or RCUS?

Arcus Biosciences has a consensus target price of $35.10, suggesting a potential upside of 15.38%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Arcus Biosciences 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58

Do analysts rate CVAC or TLX?

Telix Pharmaceuticals has a consensus target price of $21.13, indicating a potential upside of 77.97%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Telix Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Which has stronger earnings & valuation, CVAC or TLX?

CureVac has higher earnings, but lower revenue than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Telix Pharmaceuticals $803.79M 5.01 -$7.12M N/A N/A

CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 07/2/2026

Compare

CVAC vs. DNLI, NAMS, CRNX, RCUS, and TLX

Should you buy CureVac stock or one of its competitors? MarketBeat compares CureVac with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CureVac include Denali Therapeutics (DNLI), NewAmsterdam Pharma (NAMS), Crinetics Pharmaceuticals (CRNX), Arcus Biosciences (RCUS), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does CureVac compare to Denali Therapeutics?

CureVac (NASDAQ:CVAC) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Denali Therapeutics has a consensus price target of $34.25, indicating a potential upside of 32.60%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

CureVac has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Denali Therapeutics	N/A	N/A	-$512.54M	-$2.88	N/A

CureVac has a net margin of 199.92% compared to Denali Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Denali Therapeutics	N/A	-52.20%	-43.86%

17.3% of CureVac shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Denali Therapeutics had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Denali Therapeutics and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 equaled Denali Therapeutics'average media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
Denali Therapeutics	Neutral

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

CureVac beats Denali Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CureVac compare to NewAmsterdam Pharma?

CureVac (NASDAQ:CVAC) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to NewAmsterdam Pharma's net margin of -943.23%. CureVac's return on equity of -23.03% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

CureVac has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
NewAmsterdam Pharma	$22.50M	180.96	-$203.82M	-$1.79	N/A

CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
NewAmsterdam Pharma	Neutral

NewAmsterdam Pharma has a consensus price target of $49.00, suggesting a potential upside of 40.68%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

CureVac and NewAmsterdam Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

CureVac has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	578.28	-$465.32M	-$5.13	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Crinetics Pharmaceuticals has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. CureVac's return on equity of -23.03% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
CureVac	199.92%	-23.03%	-19.09%

Crinetics Pharmaceuticals presently has a consensus target price of $73.78, suggesting a potential upside of 74.70%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Crinetics Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Crinetics Pharmaceuticals had 7 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 0 mentions for CureVac. Crinetics Pharmaceuticals' average media sentiment score of 1.04 beat CureVac's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Positive
CureVac	Neutral

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Crinetics Pharmaceuticals beats CureVac on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Arcus Biosciences?

CureVac (NASDAQ:CVAC) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

CureVac has a net margin of 199.92% compared to Arcus Biosciences' net margin of -156.36%. CureVac's return on equity of -23.03% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

In the previous week, Arcus Biosciences had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Arcus Biosciences and 0 mentions for CureVac. Arcus Biosciences' average media sentiment score of 0.06 beat CureVac's score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Arcus Biosciences	Neutral

Arcus Biosciences has a consensus target price of $35.10, suggesting a potential upside of 15.38%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

CureVac has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Arcus Biosciences	$247M	15.49	-$353M	-$3.18	N/A

17.3% of CureVac shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Arcus Biosciences beats CureVac on 9 of the 16 factors compared between the two stocks.

How does CureVac compare to Telix Pharmaceuticals?

CureVac (NASDAQ:CVAC) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Telix Pharmaceuticals has a consensus target price of $21.13, indicating a potential upside of 77.97%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Telix Pharmaceuticals' score of -0.32 indicating that CureVac is being referred to more favorably in the media.

Company	Overall Sentiment
CureVac	Neutral
Telix Pharmaceuticals	Neutral

17.3% of CureVac shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CureVac has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Telix Pharmaceuticals	$803.79M	5.01	-$7.12M	N/A	N/A

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market.

CureVac has a net margin of 199.92% compared to Telix Pharmaceuticals' net margin of 0.00%. Telix Pharmaceuticals' return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Telix Pharmaceuticals	N/A	N/A	N/A

Summary

Telix Pharmaceuticals beats CureVac on 8 of the 15 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05B	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	6.47	21.61	28.02	24.70
Price / Sales	14.78	338.16	537.00	97.28
Price / Cash	4.73	147.12	49.26	57.09
Price / Book	1.39	8.66	10.96	6.46
Net Income	$175.50M	$23.81M	$3.57B	$337.01M
7 Day Performance	N/A	3.39%	2.12%	1.69%
1 Month Performance	N/A	10.81%	5.25%	3.81%
1 Year Performance	-13.62%	62.61%	33.29%	23.90%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
DNLI Denali Therapeutics	2.5662 of 5 stars	$25.90 +0.1%	$34.25 +32.2%	+75.8%	$4.11B	$330.53M	N/A	430
NAMS NewAmsterdam Pharma	2.217 of 5 stars	$33.78 -0.3%	$48.60 +43.9%	+75.5%	$3.96B	$22.50M	N/A	4	Analyst Forecast Gap Up
CRNX Crinetics Pharmaceuticals	3.606 of 5 stars	$37.60 +1.8%	$76.13 +102.5%	+41.4%	$3.95B	$7.70M	N/A	210	Positive News Analyst Forecast
RCUS Arcus Biosciences	2.1913 of 5 stars	$31.29 +0.7%	$35.10 +12.2%	+259.4%	$3.93B	$247M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. DNLI, NAMS, CRNX, RCUS, and TLX

How does CureVac compare to Denali Therapeutics?

Summary

How does CureVac compare to NewAmsterdam Pharma?

Summary

How does CureVac compare to Crinetics Pharmaceuticals?

Summary

How does CureVac compare to Arcus Biosciences?

Summary

How does CureVac compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. DNLI, NAMS, CRNX, RCUS, and TLX

How does CureVac compare to Denali Therapeutics?

Do analysts prefer CVAC or DNLI?

Which has better valuation & earnings, CVAC or DNLI?

Is CVAC or DNLI more profitable?

Do insiders and institutionals believe in CVAC or DNLI?

Does the media prefer CVAC or DNLI?

Which has more volatility and risk, CVAC or DNLI?

Summary

How does CureVac compare to NewAmsterdam Pharma?

Do insiders & institutionals hold more shares of CVAC or NAMS?

Is CVAC or NAMS more profitable?

Which has better valuation & earnings, CVAC or NAMS?

Which has more risk & volatility, CVAC or NAMS?

Does the media refer more to CVAC or NAMS?

Do analysts prefer CVAC or NAMS?

Summary

How does CureVac compare to Crinetics Pharmaceuticals?

Which has stronger earnings and valuation, CRNX or CVAC?

Which has more risk and volatility, CRNX or CVAC?

Is CRNX or CVAC more profitable?

Do analysts prefer CRNX or CVAC?

Does the media favor CRNX or CVAC?

Do insiders and institutionals hold more shares of CRNX or CVAC?

Summary

How does CureVac compare to Arcus Biosciences?

Is CVAC or RCUS more profitable?

Which has more volatility and risk, CVAC or RCUS?

Does the media refer more to CVAC or RCUS?

Do analysts recommend CVAC or RCUS?

Which has preferable valuation and earnings, CVAC or RCUS?

Do institutionals and insiders hold more shares of CVAC or RCUS?

Summary

How does CureVac compare to Telix Pharmaceuticals?

Do analysts rate CVAC or TLX?

Does the media refer more to CVAC or TLX?

Do insiders & institutionals believe in CVAC or TLX?

Which has stronger earnings & valuation, CVAC or TLX?

Which has more volatility and risk, CVAC or TLX?

Is CVAC or TLX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools